Valuation Update With 7 Day Price Move • 14h
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to CN¥95.65, the stock trades at a trailing P/E ratio of 66.1x. Average trailing P/E is 36x in the Medical Equipment industry in China. Total returns to shareholders of 74% over the past three years. Valuation Update With 7 Day Price Move • Jun 11
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to CN¥112, the stock trades at a trailing P/E ratio of 77.4x. Average trailing P/E is 38x in the Medical Equipment industry in China. Total returns to shareholders of 96% over the past three years. Declared Dividend • Jun 08
Dividend of CN¥0.60 announced Shareholders will receive a dividend of CN¥0.60. Ex-date: 10th June 2026 Payment date: 10th June 2026 Dividend yield will be 0.5%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by both earnings (41% earnings payout ratio) and cash flows (58% cash payout ratio). The dividend has increased by an average of 16% per year over the past 5 years and payments have been stable during that time. EPS is expected to grow by 95% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 27
First quarter 2026 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.40 (up from CN¥0.39 in 1Q 2025). Revenue: CN¥174.5m (up 19% from 1Q 2025). Net income: CN¥47.2m (up 1.1% from 1Q 2025). Profit margin: 27% (down from 32% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. Announcement • Apr 25
Qingdao NovelBeam Technology Co.,Ltd., Annual General Meeting, May 22, 2026 Qingdao NovelBeam Technology Co.,Ltd., Annual General Meeting, May 22, 2026, at 10:00 China Standard Time. Location: The Company's Meeting Room, Qingdao, Shandong China Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥86.73, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 26x in the Medical Equipment industry in China. Total returns to shareholders of 23% over the past three years. New Risk • Mar 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Mar 30
Qingdao NovelBeam Technology Co.,Ltd. to Report Q1, 2026 Results on Apr 25, 2026 Qingdao NovelBeam Technology Co.,Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026 Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment improves as stock rises 32% After last week's 32% share price gain to CN¥47.83, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 24x in the Medical Equipment industry in China. Total loss to shareholders of 28% over the past three years. Reported Earnings • Mar 02
Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2025 results: EPS: CN¥1.44 (up from CN¥1.12 in FY 2024). Revenue: CN¥602.6m (up 36% from FY 2024). Net income: CN¥171.6m (up 27% from FY 2024). Profit margin: 28% (down from 31% in FY 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.5%. Earnings per share (EPS) missed analyst estimates by 3.0%. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings. Announcement • Dec 26
Qingdao NovelBeam Technology Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 25, 2026 Qingdao NovelBeam Technology Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 25, 2026 Reported Earnings • Oct 25
Third quarter 2025 earnings released: EPS: CN¥0.52 (vs CN¥0.23 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.52 (up from CN¥0.23 in 3Q 2024). Revenue: CN¥182.0m (up 85% from 3Q 2024). Net income: CN¥61.9m (up 131% from 3Q 2024). Profit margin: 34% (up from 27% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings. Announcement • Sep 30
Qingdao NovelBeam Technology Co.,Ltd. to Report Q3, 2025 Results on Oct 25, 2025 Qingdao NovelBeam Technology Co.,Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025 Announcement • Jun 30
Qingdao NovelBeam Technology Co.,Ltd. to Report First Half, 2025 Results on Aug 23, 2025 Qingdao NovelBeam Technology Co.,Ltd. announced that they will report first half, 2025 results on Aug 23, 2025 Declared Dividend • Jun 02
Dividend increased to CN¥0.60 Dividend of CN¥0.60 is 9.1% higher than last year. Ex-date: 6th June 2025 Payment date: 6th June 2025 Dividend yield will be 1.5%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by earnings (50% earnings payout ratio) but not covered by cash flows (110% cash payout ratio). The dividend has increased by an average of 20% per year over the past 4 years and payments have been stable during that time. EPS is expected to grow by 84% over the next 3 years, which should provide support to the dividend and adequate earnings cover. New Risk • May 03
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Cash payout ratio: 110% Dividend yield: 1.7% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Major Estimate Revision • May 02
Consensus revenue estimates fall by 22% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥705.8m to CN¥550.6m. EPS estimate fell from CN¥2.04 to CN¥1.82 per share. Net income forecast to grow 63% next year vs 39% growth forecast for Medical Equipment industry in China. Consensus price target of CN¥35.00 unchanged from last update. Share price was steady at CN¥34.55 over the past week. Reported Earnings • Apr 25
First quarter 2025 earnings released: EPS: CN¥0.39 (vs CN¥0.32 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.39 (up from CN¥0.32 in 1Q 2024). Revenue: CN¥146.9m (up 25% from 1Q 2024). Net income: CN¥46.7m (up 22% from 1Q 2024). Profit margin: 32% (in line with 1Q 2024). Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings. Announcement • Apr 25
Qingdao NovelBeam Technology Co.,Ltd., Annual General Meeting, May 15, 2025 Qingdao NovelBeam Technology Co.,Ltd., Annual General Meeting, May 15, 2025, at 10:00 China Standard Time. Location: The Company's Meeting Room, Qingdao, Shandong China Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to CN¥29.40, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 20x in the Medical Equipment industry in China. Total loss to shareholders of 39% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.83 per share. Announcement • Mar 28
Qingdao NovelBeam Technology Co.,Ltd. to Report Q1, 2025 Results on Apr 25, 2025 Qingdao NovelBeam Technology Co.,Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025 Announcement • Mar 05
Qingdao NovelBeam Technology Co.,Ltd. (SHSE:688677) announces an Equity Buyback for CNY 100 million worth of its shares. Qingdao NovelBeam Technology Co.,Ltd. (SHSE:688677) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of shares. The shares will be repurchased at a price of not more than CNY 59 per share. The shares purchased will be used to implement employee stock ownership plans or equity incentives. The source of funds for the share repurchase is the company's own funds. The program will be valid for 12 months. Reported Earnings • Feb 26
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥1.12 (down from CN¥1.20 in FY 2023). Revenue: CN¥440.7m (down 6.4% from FY 2023). Net income: CN¥134.9m (down 7.4% from FY 2023). Profit margin: 31% (in line with FY 2023). Revenue missed analyst estimates by 20%. Earnings per share (EPS) also missed analyst estimates by 26%. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 10% per year, which means it is performing significantly worse than earnings. Announcement • Dec 27
Qingdao NovelBeam Technology Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025 Qingdao NovelBeam Technology Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025 Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: CN¥0.23 (vs CN¥0.23 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.23 (down from CN¥0.23 in 3Q 2023). Revenue: CN¥98.3m (down 9.4% from 3Q 2023). Net income: CN¥26.8m (down 7.0% from 3Q 2023). Profit margin: 27% (in line with 3Q 2023). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥32.05, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 19x in the Medical Equipment industry in China. Total loss to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥19.72 per share. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.5% average weekly change). Announcement • Sep 30
Qingdao NovelBeam Technology Co.,Ltd. to Report Q3, 2024 Results on Oct 25, 2024 Qingdao NovelBeam Technology Co.,Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥31.25, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 18x in the Medical Equipment industry in China. Total loss to shareholders of 59% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥19.63 per share. Announcement • Jun 29
Qingdao NovelBeam Technology Co.,Ltd. to Report First Half, 2024 Results on Aug 16, 2024 Qingdao NovelBeam Technology Co.,Ltd. announced that they will report first half, 2024 results on Aug 16, 2024 Price Target Changed • Jun 28
Price target decreased by 11% to CN¥54.25 Down from CN¥60.75, the current price target is an average from 2 analysts. New target price is 37% above last closing price of CN¥39.48. Stock is down 30% over the past year. The company is forecast to post earnings per share of CN¥1.74 for next year compared to CN¥1.20 last year. Buy Or Sell Opportunity • May 27
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 21% to CN¥42.85. The fair value is estimated to be CN¥54.69, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 11%. Revenue is forecast to grow by 89% in 2 years. Earnings are forecast to grow by 116% in the next 2 years. Major Estimate Revision • May 01
Consensus EPS estimates fall by 10% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥662.3m to CN¥607.5m. EPS estimate also fell from CN¥1.89 per share to CN¥1.70 per share. Net income forecast to grow 65% next year vs 49% growth forecast for Medical Equipment industry in China. Consensus price target of CN¥59.00 unchanged from last update. Share price rose 9.3% to CN¥44.78 over the past week. Announcement • Apr 26
Qingdao NovelBeam Technology Co.,Ltd., Annual General Meeting, May 17, 2024 Qingdao NovelBeam Technology Co.,Ltd., Annual General Meeting, May 17, 2024, at 10:00 China Standard Time. Location: The Company's Meeting Room, Qingdao, Shandong China Reported Earnings • Apr 25
First quarter 2024 earnings released: EPS: CN¥0.32 (vs CN¥0.40 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.32 (down from CN¥0.40 in 1Q 2023). Revenue: CN¥117.6m (down 21% from 1Q 2023). Net income: CN¥38.4m (down 21% from 1Q 2023). Profit margin: 33% (in line with 1Q 2023). Revenue is forecast to grow 36% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥40.44, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 20x in the Medical Equipment industry in China. Total loss to shareholders of 22% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥18.80 per share. Announcement • Mar 30
Qingdao NovelBeam Technology Co.,Ltd. to Report Q1, 2024 Results on Apr 25, 2024 Qingdao NovelBeam Technology Co.,Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024 Reported Earnings • Feb 24
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥1.21 (down from CN¥1.50 in FY 2022). Revenue: CN¥470.6m (down 1.3% from FY 2022). Net income: CN¥145.9m (down 20% from FY 2022). Profit margin: 31% (down from 38% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 7.6%. Earnings per share (EPS) also missed analyst estimates by 11%. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥55.88, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 21x in the Medical Equipment industry in China. Total loss to shareholders of 33% over the past year. Reported Earnings • Oct 20
Third quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.49 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.23 (down from CN¥0.49 in 3Q 2022). Revenue: CN¥108.4m (down 24% from 3Q 2022). Net income: CN¥28.9m (down 52% from 3Q 2022). Profit margin: 27% (down from 42% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Announcement • Jun 28
Qingdao NovelBeam Technology Co.,Ltd. to Report First Half, 2023 Results on Aug 29, 2023 Qingdao NovelBeam Technology Co.,Ltd. announced that they will report first half, 2023 results on Aug 29, 2023 Valuation Update With 7 Day Price Move • Jun 13
Investor sentiment deteriorates as stock falls 31% After last week's 31% share price decline to CN¥56.14, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 26x in the Medical Equipment industry in China. Total loss to shareholders of 34% over the past year. Board Change • Jun 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. Supervisor Xin Liu was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Apr 22
First quarter 2023 earnings released: EPS: CN¥0.56 (vs CN¥0.41 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.56 (up from CN¥0.41 in 1Q 2022). Revenue: CN¥148.4m (up 59% from 1Q 2022). Net income: CN¥48.5m (up 35% from 1Q 2022). Profit margin: 33% (down from 38% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Reported Earnings • Oct 21
Third quarter 2022 earnings released: EPS: CN¥0.69 (vs CN¥0.38 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.69 (up from CN¥0.38 in 3Q 2021). Revenue: CN¥143.4m (up 74% from 3Q 2021). Net income: CN¥60.0m (up 82% from 3Q 2021). Profit margin: 42% (up from 40% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥112, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 23x in the Medical Equipment industry in China. Total returns to shareholders of 2.4% over the past year. Valuation Update With 7 Day Price Move • Sep 13
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥105, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 22x in the Medical Equipment industry in China. Total returns to shareholders of 12% over the past year. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.38 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.51 (up from CN¥0.38 in 2Q 2021). Revenue: CN¥102.7m (up 50% from 2Q 2021). Net income: CN¥44.1m (up 35% from 2Q 2021). Profit margin: 43% (down from 48% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 52%, compared to a 26% growth forecast for the Medical Equipment industry in China. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS exceeds analyst expectations First quarter 2022 results: EPS: CN¥0.41 (up from CN¥0.36 in 1Q 2021). Revenue: CN¥93.5m (up 39% from 1Q 2021). Net income: CN¥35.8m (up 37% from 1Q 2021). Profit margin: 38% (in line with 1Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.4%. Over the next year, revenue is forecast to grow 54%, compared to a 25% growth forecast for the industry in China. Reported Earnings • Feb 28
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: CN¥1.41 (down from CN¥1.48 in FY 2020). Revenue: CN¥309.7m (up 13% from FY 2020). Net income: CN¥117.8m (up 22% from FY 2020). Profit margin: 38% (up from 35% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥74.49, the stock trades at a trailing P/E ratio of 57.5x. Average trailing P/E is 35x in the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Jan 25
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥75.28, the stock trades at a trailing P/E ratio of 58.1x. Average trailing P/E is 36x in the Medical Equipment industry in China. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.39 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: CN¥82.5m (up 30% from 3Q 2020). Net income: CN¥32.9m (up 30% from 3Q 2020). Profit margin: 40% (in line with 3Q 2020). Reported Earnings • Aug 26
Second quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.39 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥68.4m (up 7.4% from 2Q 2020). Net income: CN¥32.7m (up 29% from 2Q 2020). Profit margin: 48% (up from 40% in 2Q 2020). The increase in margin was primarily driven by higher revenue. Valuation Update With 7 Day Price Move • Aug 24
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥91.44, the stock trades at a trailing P/E ratio of 66.7x. Average trailing P/E is 39x in the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • May 18
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥98.56, the stock trades at a trailing P/E ratio of 71.9x. Average trailing P/E is 39x in the Medical Equipment industry in China. Reported Earnings • May 01
First quarter 2021 earnings released: EPS CN¥0.36 (vs CN¥0.21 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥67.2m (up 12% from 1Q 2020). Net income: CN¥26.1m (up 91% from 1Q 2020). Profit margin: 39% (up from 23% in 1Q 2020). The increase in margin was primarily driven by higher revenue. Reported Earnings • Mar 27
Full year 2020 earnings released: EPS CN¥1.43 (vs CN¥1.08 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥275.2m (up 8.8% from FY 2019). Net income: CN¥93.1m (up 29% from FY 2019). Profit margin: 34% (up from 28% in FY 2019).